Switching to Alemtuzumab From Subcutaneous Interferon Beta-1a After CARE-MS I Further Improved MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis (P7.261)
Bibliographic record
Abstract
OBJECTIVE: Examine magnetic resonance imaging (MRI) outcomes in patients who switched to alemtuzumab after receiving subcutaneous interferon beta-1a (SC IFNB-1a) in CARE-MS I. BACKGROUND: In the 2-year CARE-MS I core study (NCT00530348) of treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzumab treatment improved many MRI outcomes, including reductions in MRI lesion activity and brain volume loss, compared with SC IFNB-1a. A CARE-MS extension (NCT00930553) is ongoing. DESIGN/METHODS: In CARE-MS I, SC IFNB-1a-treated patients received 44 μg 3 times/week. In the first 2 years of the extension, former SC IFNB-1a-treated patients received 2 annual alemtuzumab courses (12 mg/day). MRI outcomes assessed at baseline, and yearly included gadolinium (Gd)-enhancing, new/enlarging T2 hyperintense, and new T1 hypointense lesion activity, and MRI activity-free (absence of Gd-enhancing and new/enlarging T2 lesions). RESULTS: The extension enrolled 144 (83.2[percnt]) former SC IFNB-1a-treated patients; 91.7[percnt] received 2 alemtuzumab courses; 4.9[percnt] received 1 alemtuzumab course, and 5.6[percnt] discontinued from the study. Proportions of patients free of lesion activity increased after switching to alemtuzumab (Year 4) compared with Year 2 on SC IFNB-1a for Gd-enhancing (96.2[percnt] vs 80.8[percnt]), new/enlarging T2 (81.7[percnt] vs 59.8[percnt]), and new T1 lesions (94.7[percnt] vs 82.4[percnt]). Proportion of patients MRI activity-free was higher on alemtuzumab (Year 4) vs Year 2 on SC IFNB-1a (81.7[percnt] vs 59.2[percnt]). Rate of new lesion formation per year declined from Year 2 on SC IFNB-1a after switching to alemtuzumab (Year 4) for new Gd-enhancing (0.31 to 0.04); new/enlarging T2 (1.63 to 0.68); new T1 (0.47 to 0.11). CONCLUSIONS: Switching from SC IFNB-1a to alemtuzumab improved the proportion of patients free of MRI activity and reduced rate of new lesion formation. These findings further confirm the superior efficacy of alemtuzumab in RRMS patients who received prior disease-modifying therapy. Study Supported by: Genzyme, a Sanofi company, and Bayer Healthcare Pharmaceuticals
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".